Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

• Status: Terminated
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an anti-coagulant for a period of one year to see if there are any significant changes in the degree of left atrial structural remodeling in these patients. The investigators hypothesize that there will be a significant decrease in the degree of left atrial structural remodeling (fibrosis) in AF patients treated with dabigatran.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Treatments: Dabigatran

Criteria

Inclusion Criteria:

1. Patients with all types of non-valvular AF (includes paroxysmal, persistent and permanent AF)

2. Candidate for anticoagulation therapy

3. No contra-indication for LGE-MRI

4. Patients age 18 and older

5. Patients who are able to provide informed consent to participate in the study

Exclusion Criteria:

1. Patients who have already undergone an atrial fibrillation ablation procedure.

2. Patients with active contra-indications to any anticoagulant agent.

3. Other major bleeding disorders or risk factors that would place the patient at risk of bleeding.

4. Recent surgery (within 30 days).

5. Renal insufficiency, severe kidney disorders/diseases, GFR < 30mg/dL (Gadolinium contraindication).

6. Advanced liver disease.

7. Any health related Gadolinium/MRI contraindications: Pacemaker devices, etc.

8. Pregnant, planning to be become pregnant or nursing women

9. Individuals who are unable to provide informed consent

10. Contraindicated for Pradaxa® .

11. Patients the Investigators feel are inappropriate for the study

12. Patients who cannot give informed consent